More than 10 million US patients will regain easy access to Eli Lilly & Co.’s obesity shot Zepbound through insurance after CVS Health Corp. reversed a controversial decision to restrict it for certain drug plans.
Market Samachar is a news aggregator. This article was originally published by Bloomberg. Tap the button above to read the full story on their site.